SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia

Francesca Romana Mauro, Giuseppe Bandini, Giovanni Barosi, Atto Billio, Maura Brugiatelli, Antonio Cuneo, Francesco Lauria, Vincenzo Liso, Monia Marchetti, Giovanna Meloni, Marco Montillo, Pierluigi Zinzani, Sante Tura

Research output: Contribution to journalArticle

Abstract

By using GRADE system we updated the guidelines for management of CLL issued in 2006 from SIE, SIES and GITMO group. We recommended fludarabine, cyclophosphamide, rituximab (FCR) in younger and selected older patients with a good fitness status, no unfavourable genetics (deletion 17p and/or p53 mutations), and a less toxic treatment in nonfit and elderly patients. In patients without unfavourable genetics, relapsed after 24 months the same initial treatment including rituximab can be considered. In patients with unfavourable genetics, refractory or relapsed within 24 months from a prior fludarabine-based treatment, allogeneic SCT or experimental treatments should be given.

Original languageEnglish
Pages (from-to)459-466
Number of pages8
JournalLeukemia Research
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 2012

    Fingerprint

Keywords

  • Alemtuzumab
  • Chronic lymphocytic leukemia
  • Guideline
  • Recommendation
  • Rituximab

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Mauro, F. R., Bandini, G., Barosi, G., Billio, A., Brugiatelli, M., Cuneo, A., Lauria, F., Liso, V., Marchetti, M., Meloni, G., Montillo, M., Zinzani, P., & Tura, S. (2012). SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia. Leukemia Research, 36(4), 459-466. https://doi.org/10.1016/j.leukres.2011.08.013